Safety Information

Zinforo®: Low risk of interactions and tolerability established in patients with comorbidities1-5

References:
  1. Local Product Document. Zinforo® version LPDZIN072021.
  2. File T, Low D, Eckburg P, et al. Clin Infect Dis 2010; 51:1395–405.
  3. Ramani A, Udeani G, Evans J, et al. J Chemother 2014; 26:229–34.
  4. Corey G, Wilcox M, Talbot G, et al. Clin Infect Dis 2010; 51:641–50.
  5. Casapao A, Davis S, Barr V, et al. Antimicrob Agents Chemother 2014; 58:2541–6.
  6. Lodise TP, Low DE. Drugs 2012; 72:1473–93.

Low incidence of discontinuation due to adverse events1-3

*Comparators from Zinforo® clinical trials for the treatment of cSSTI and CAP.2

Safety and Tolerability in cSSTIs
Both therapy groups exhibited comparable incidences of treatment-emergent adverse events (AEs). Pruritus was more frequent with the vancomycin plus aztreonam group vs. the ceftaroline group (8.2% vs 3.5%). A possible allergic reaction was the most prominent factor for premature discontinuation of the therapy intervention (1.9% for ceftaroline and 2.9% for vancomycin plus aztreonam, 2.9%)3

Adapted from: Corey GR, et al. J Antimicrob Chemother. 2010;65(Suppl 4):iv41–iv51.

Please refer to full Prescribing Information for the complete list of adverse events.

cSSTI: complicated skin and soft tissue infections; CAP: community acquired pneumonia

References:
  1. File T, Low D, Eckburg P, et al. Clin Infect Dis 2010; 51:1395–405.
  2. Laudano JB. J Antimicrob Chemother 2011; 66(Suppl. 3):iii11–iii18.
  3. Corey G, Wilcox M, Talbot G, et al. Clin Infect Dis 2010; 51:641–50.

PP-ZFO-IND-0279.  09 December 2021
Please click on Prescribing Information link to view safety and adverse events information of Zinforo.
For the use only of registered medical practitioner, or a hospital or a laboratory.